Stock Analysis

Alpha Tau Medical And 2 Other Penny Stocks Worth Your Attention

NYSEAM:MYND
Source: Shutterstock

As the U.S. stock market surges on news of a trade deal with the UK, investors are keenly observing how such developments might influence various sectors, including smaller-cap stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for growth at lower price points despite being considered a somewhat outdated term. By focusing on strong financials and solid fundamentals, these under-the-radar investments can present compelling prospects for those looking to explore beyond the mainstream market options.

Advertisement

Top 10 Penny Stocks In The United States

NameShare PriceMarket CapRewards & Risks
Safe Bulkers (NYSE:SB)$3.39$358.57M✅ 4 ⚠️ 3 View Analysis >
Tuya (NYSE:TUYA)$2.29$1.39B✅ 3 ⚠️ 3 View Analysis >
Smith Micro Software (NasdaqCM:SMSI)$1.045$16.42M✅ 4 ⚠️ 4 View Analysis >
Kiora Pharmaceuticals (NasdaqCM:KPRX)$3.35$9.9M✅ 4 ⚠️ 1 View Analysis >
Flexible Solutions International (NYSEAM:FSI)$3.60$45.28M✅ 4 ⚠️ 2 View Analysis >
Imperial Petroleum (NasdaqCM:IMPP)$2.63$89.65M✅ 3 ⚠️ 2 View Analysis >
Heritage Global (NasdaqCM:HGBL)$1.975$70.64M✅ 3 ⚠️ 2 View Analysis >
BAB (OTCPK:BABB)$0.84$6.12M✅ 2 ⚠️ 3 View Analysis >
Lifetime Brands (NasdaqGS:LCUT)$3.29$72.4M✅ 3 ⚠️ 2 View Analysis >
CBAK Energy Technology (NasdaqCM:CBAT)$0.843$74.37M✅ 4 ⚠️ 1 View Analysis >

Click here to see the full list of 767 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Alpha Tau Medical (NasdaqCM:DRTS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company specializing in the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for treating solid cancer, with a market cap of $182.29 million.

Operations: Alpha Tau Medical Ltd. currently has no reported revenue segments as it focuses on developing its diffusing alpha-emitters radiation therapy for solid cancer treatment.

Market Cap: $182.29M

Alpha Tau Medical Ltd. is a pre-revenue company focusing on its innovative Alpha DaRT technology for cancer treatment, recently receiving FDA approval to initiate a pilot study for recurrent glioblastoma. Despite no revenue, the company maintains financial stability with short-term assets of US$64.2 million surpassing liabilities and sufficient cash runway for over two years. The recent follow-on equity offering raised US$36.86 million, potentially bolstering its development efforts but increasing share dilution risk. Though unprofitable with rising losses, the seasoned management team provides experienced leadership in navigating these challenges as they advance clinical trials and product development.

NasdaqCM:DRTS Financial Position Analysis as at May 2025
NasdaqCM:DRTS Financial Position Analysis as at May 2025

Mynd.ai (NYSEAM:MYND)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Mynd.ai, Inc. operates in the technology sector by offering interactive flat panel display products and has a market capitalization of $33.21 million.

Operations: The company generates revenue from its eLMTree segment, amounting to $267.38 million.

Market Cap: $33.21M

Mynd.ai, Inc., with a market cap of US$33.21 million, operates in the technology sector but faces challenges typical of penny stocks. The company reported a significant revenue drop to US$267.38 million from the previous year and experienced increased net losses to US$95.72 million. Despite this, Mynd.ai maintains more cash than debt and covers both short- and long-term liabilities with its assets. Recent executive changes see Arthur Giterman stepping in as CEO after Vin Riera's departure, potentially impacting strategic direction as Giterman continues his dual role as CFO amidst high share price volatility and recent buybacks totaling 204,888 shares for US$0.44 million.

NYSEAM:MYND Revenue & Expenses Breakdown as at May 2025
NYSEAM:MYND Revenue & Expenses Breakdown as at May 2025

Granite Point Mortgage Trust (NYSE:GPMT)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Granite Point Mortgage Trust Inc. is a real estate investment trust that focuses on originating, investing in, and managing senior floating-rate commercial mortgage loans and other debt-related commercial real estate investments in the United States, with a market cap of approximately $91.97 million.

Operations: Granite Point Mortgage Trust Inc. does not report distinct revenue segments, focusing instead on its core activities within the United States.

Market Cap: $91.97M

Granite Point Mortgage Trust Inc., with a market cap of approximately US$91.97 million, operates in the mortgage REIT sector but remains unprofitable, reporting a net loss of US$7.02 million for Q1 2025, an improvement from the previous year's substantial losses. Despite its financial challenges and high debt levels, Granite Point maintains sufficient short-term assets to cover liabilities and has reduced its debt-to-equity ratio over five years. The company declared dividends on both common and preferred stocks but struggles with earnings coverage. Revenue forecasts indicate significant growth potential despite ongoing profitability issues, reflecting typical volatility associated with penny stocks.

NYSE:GPMT Debt to Equity History and Analysis as at May 2025
NYSE:GPMT Debt to Equity History and Analysis as at May 2025

Turning Ideas Into Actions

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com